Group items tagged

In May of 2013 the National Institute of Neurological Disorders and Stroke (NINDS), with input from the National Institute on Aging (NIA), held an Alzheimer's Disease-Related Dementias Conference in response to the National Plan to Address Alzheimer's Disease. The Conference brought together national and international experts and members of the public to develop research priorities for accelerating the development of therapies for the Alzheimer's disease-related dementias (ADRDs). The ADRD 2013 research recommendations that resulted are part of the National Plan to Address Alzheimer's Disease. This FOA addresses the National Plan's highest priority for human-based research on vascular contributions to cognitive impairment and dementia (VCID): to develop noninvasive markers of key vascular processes related to VCID in Alzheimer's and related dementias. The research program initiated here underscores the need to facilitate the development of biomarkers to improve the efficiency and outcome of Phase II and III clinical trials and advance therapeutic development. These companion FOAs (RFA-NS-16-019, i.e. this FOA; and RFA-NS-16-020 for the Biomarkers Development Projects) establish the Small Vessel VCID Biomarkers Consortium, and are focused on small vessel (i.e. arterioles, capillaries, and venules) VCID in vascular cognitive impairment (VCI), vascular dementia, and all mixed and pure cognitive impairment and dementias with contributing small vessel vascular disease, including such as commonly occurs in sporadic Alzheimer's disease. Awards funded under these two FOAs create a consortium and infrastructure to complete development projects as well as planning that will enable follow-up activities (to be carried out under future separate funding; for example large scale multi-site validation studies and other activities, for future FDA qualification of small vessel VCID biomarkers and use in clinical trials).

The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimer's disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimer's disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicit research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimer's disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research

The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

This FOA invites applications for a National Alzheimer's Coordinating Center (NACC) whose purpose is to serve NIA and the Alzheimer's disease (AD) and Alzheimer's disease- related dementias (AD/ADRD) field as 1) a national data resource, collecting data from the Alzheimer's Disease Research Centers (ADRCs), affiliated data, and sample repositories; 2) a facilitator of current and future AD/ADRD research; and 3) the central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

This funding opportunity announcement(FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for improvement of ligand specificity and selectivity, initial screening of ligands in appropriated animal models, and radioligand formulation and first-in-human testing. Applications must include an administrative core, a medicinal chemistry core, a clincial core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

This FOA invites Research and Development Center (P30) grant applications in demography, economics and health services research relevant to Alzheimer's Disease and Alzheimer's Related Dementias (AD/ADRD). Areas of focus that are especially encouraged are: a) national and international population trends in cognitive aging and AD/ADRD; b) demography of dementia care and caregiving; c) economic burden of AD/ADRD; d) impact of health care systems and long-term supports and services on outcomes for persons with dementia and their care providers; e) impact of health care financing policies on outcomes for persons with dementia and their care providers; f) how regulatory and economic incentives affect access, quality and health outcomes in health and long-term care systems for persons with dementia; g) disparities in quality and access to dementia care; h) effects of population-level health delivery and care interventions on outcomes of persons with dementia; and i) national and international projections of dementia caseload, incidence and prevalence. Center grant applications must include two mandatory Cores and may choose among three optional Cores. Centers are required to work collaboratively with the Coordinating Center to be funded via RFA-AG-20-003.  

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), in partnership with the National Institute on Aging (NIA), announces an opportunity for NIBIB-supported investigators to request administrative supplements to develop new tools, technologies and approaches for the prevention, diagnosis, treatment and understanding of Alzheimer's Disease and Alzheimer's-disease-related dementias (AD/ADRD). These supplements will be funded by NIA as part of the NIA strategic plan to support the development of innovative strategies to prevent, diagnose and treat AD/ADRD.

The BrightFocus Foundation provides research funds for U.S. and international researchers pursuing high-risk studies that illuminate areas for which there currently is little understanding, helping to bring to light crucial knowledge about Alzheimer's disease, glaucoma, and macular degeneration. The organization's mission is to save mind and sight by funding innovative research worldwide and by promoting better health through education. To that end, the foundation is accepting applications for its Alzheimer's Disease Research and National Glaucoma Research programs. 1) Alzheimer's Disease Research: Grants of up to $300,000 over three years will be awarded to researchers for innovative investigator-initiated research projects. The program is designed to give scientists the opportunity to develop the preliminary data necessary to be considered competitive for larger government or corporate types of sponsorship. Applications must be received no later than October 18, 2017. 2) National Glaucoma Program: Grants of up to $150,000 over two years will be awarded to researchers for innovative investigator-initiated glaucoma-related research projects. The program is designed to give scientists the opportunity to develop the preliminary data necessary to be considered competitive for larger government or corporate types of sponsorship. Typically these awards are made to junior investigators, or to more established investigators who are proposing particularly innovative research.

Applicants will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits.

This Funding Opportunity Announcement (FOA) requests submission of applications for the National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family Based Study (FBS). Analysis of families that are multiply affected with Alzheimer's disease (AD) provides distinct advantages for characterizing the impact of genetic variants on disease risk. First, multiplex families are likely to be enriched for genetic variants associated with increased risk, providing increased statistical power to estimate the effects. Second, analysis of multiply affected families provides insight into the remaining unknown genetic influences (i.e., the "residual heritability") as well as antecedent modifying factors that interact with identified genetic variants to influence disease risk. Third, family members at risk are followed at regular intervals, facilitating prospective investigation of the effects of the genetic variants on age-at-onset as well as the modifying effects of antecedent risk and protective factors. Finally, family data can provide information regarding the influence of known variants on the rate of disease progression and the residual heritability of disease progression.

The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. The goal of developing new therapies will be achieved by providing award recipients with both research funding and committed project support by a team of pharmaceutical industry experts. Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, or slow Alzheimer's disease, other dementias, and cognitive aging.

This FOA invites existing Alzheimer's Disease Patient Registry cooperative agreements that are described in Part 2, Section I to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application.

This Funding Opportunity Announcement (FOA) invites applications focused on interpersonal processes in the context of triadic interactions in clinical contexts involving caregivers, individuals with Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD), and health care practitioners and the impact of those processes on patient outcomes. The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and healthcare practitioners and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.

This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias. The program seeks to stimulate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, Alzheimer's disease and healthy brain aging.

Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies. The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects. Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimer's disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

The NIA Behavioral and Social Research LEaders in Alzheimer's Disease and Its Related Dementias (NIA BSR LEADR) program supports individual scientists of exceptional creativity who propose to use behavioral and social science perspectives and approaches for highly innovative, impactful, and potentially transformative theoretical, empirical, and clinical research addressing the challenges raised by Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) for individuals, their families, and society. Applications are welcome from individuals with diverse backgrounds. NIA encourages applications on a variety of AD/ADRD topics in which behavioral and social research can contribute, such as dementia care, dementia caregiver research, cognitive and dementia epidemiology, behavioral and social pathways of AD/ADRD, early psychological changes preceding AD/ADRD, prevention of AD/ADRD, and disparities in AD/ADRD or dementia-related outcomes.

The overall goal of this FOA is to support the development of a collaborative research and resource network to synergize the expertise, skills, and resources of investigators within the geriatric emergency medicine and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research communities to identify and address research gaps towards optimizing recognition and emergency care of older adults with AD/ADRD. Support is provided for up to 2 years of planning/development (R61 phase) of a milestone-driven infrastructure including the initial identification of top-priority research gaps and the establishment of strategies to address them. Areas identified as needing additional evidence-based research include, but are not limited to, pre-emergency department (ED) strategies to avoid non-emergency ED visits, recognition of early cognitive impairment in the ED, strategies to optimize the ED environment and providers for patients with AD/ADRD, development of safe disposition criteria, and methods to minimize system fragmentation within and across health and social services.